MOSCOW: Mass testing of Russia’s first potential COVID-19 vaccine to get domestic regulatory approval will involve more than 40,000 people, the TASS news agency cited the vaccine’s developer as saying on Thursday.
The vaccine, called “Sputnik V” in homage to the world’s first satellite launched by the Soviet Union, has been hailed as safe and effective by Russian authorities and scientists following two months of small-scale human trials, the results of which have not been made public yet.
The vaccine is administered in two doses and consists of two serotypes of a human adenovirus, each carrying an S-antigen of the new coronavirus, which enter human cells and produce an immune response.
The platform used for the vaccine was developed by Russian scientists over two decades and had formed the basis for several vaccines in the past, including those against Ebola.
Authorities hope it will allow the Russian economy, which has been battered by fallout from the virus, to return to full capacity.
Kirill Dmitriev, head of Russia’s sovereign wealth fund, said Russia had already received foreign requests for 1 billion doses of COVID-19 vaccine. He said the vaccine was also expected to be produced in Brazil.
